With a market cap of $681.8 billion, Eli Lilly and Company (LLY) is a leading global pharmaceutical company focused on ...

This was the stock's fifth consecutive day of gains.

The stock's rise snapped a five-day losing streak.

Eli Lilly surges 11% on strong phase-three trial data for its weight-loss and diabetes pill, boosting healthcare sentiment. S&P Futures Rebound While Dow Struggles On UnitedHealth Collapse Daily E ...

Rising sales of Mounjaro helped Eli Lilly beat expectations for revenue in the most recent quarter. (Sandy Huffaker for The Washington Post/Getty Images) Eli Lilly stock is poised to set a new ...

Sources: FactSet, Dow Jones Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet ...

The Indianapolis-based pharmaceutical company said it expects fourth-quarter revenue of $13.5 billion, around $400 million below the low end of its last estimated range issued in October.

Boundless demand for weight-loss and diabetes drugs fueled a sharp rise in Eli Lilly’s sales and profits—and the drugmaker still can’t make enough. Fourth-quarter sales of Lilly’s diabetes ...

Eli Lilly’s Friday stock gain puts its market capitalization on pace to close above Johnson & Johnson’s for the first time since October 1997, according to Dow Jones Market Data.